Drugs / Bacillus Calmette Guerin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06255964 Background | Feb → Oct 2024 overdue | urinary bladder cancer | SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette Guerin | “A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer” NCT06255964 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06255964 ↗ |
| Route | Other | “IAP0971 combined with BCG,Bladder perfusion” NCT06255964 ↗ |